SEER wins patent challenge from Bruker subsidiaries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
March 30, 2026 7:00 AM EDTREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the 360 Patent). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the 360 Patent.
The 360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that... More
